State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019
R Lemal, O Tournilhac - Journal for immunotherapy of cancer, 2019 - Springer
Experience in the use of CAR T cells to treat CLL is limited, but safety and efficacy data are
encouraging, suggesting that it may be possible to use CAR T cells in populations of CLL …
encouraging, suggesting that it may be possible to use CAR T cells in populations of CLL …
Simplified geriatric assessment in older patients with diffuse large B-cell lymphoma: the prospective elderly project of the Fondazione Italiana Linfomi
F Merli, S Luminari, A Tucci, A Arcari… - Journal of clinical …, 2021 - ascopubs.org
PURPOSE To prospectively validate the use of a simplified geriatric assessment (sGA) at
diagnosis and to integrate it into a prognostic score for older patients with diffuse large B-cell …
diagnosis and to integrate it into a prognostic score for older patients with diffuse large B-cell …
New treatment options in elderly patients with diffuse large B-cell lymphoma
A Arcari, F Cavallo, B Puccini, D Vallisa - Frontiers in Oncology, 2023 - frontiersin.org
Most patients with Diffuse Large B-cell Lymphoma (DLBCL) are old (> 65 years of age) and
this population is expected to increase in the following years. A simplified geriatric …
this population is expected to increase in the following years. A simplified geriatric …
High total metabolic tumor volume at baseline predicts survival independent of response to therapy
L Vercellino, AS Cottereau… - Blood, The Journal …, 2020 - ashpublications.org
Early identification of ultra-risk diffuse large B-cell lymphoma (DLBCL) patients is needed to
aid stratification to innovative treatment. Previous studies suggested high baseline total …
aid stratification to innovative treatment. Previous studies suggested high baseline total …
[HTML][HTML] Treatment strategies and outcomes in diffuse large B-cell lymphoma among 1011 patients aged 75 years or older: a Danish population-based cohort study
MB Juul, PH Jensen, H Engberg, S Wehberg… - European Journal of …, 2018 - Elsevier
Background Optimal treatment strategy for the oldest patients with diffuse large B-cell
lymphoma (DLBCL) remains controversial, as this group often is precluded from clinical …
lymphoma (DLBCL) remains controversial, as this group often is precluded from clinical …
Exploring cost-effectiveness of the comprehensive geriatric assessment in geriatric oncology: a narrative review
S Zuccarino, F Monacelli, R Antognoli, A Nencioni… - Cancers, 2022 - mdpi.com
Simple Summary The Comprehensive Geriatric Assessment is a multidimensional and
multidisciplinary evaluation designed for elderly patients with the goal of structuring tailored …
multidisciplinary evaluation designed for elderly patients with the goal of structuring tailored …
Diffuse large B-cell lymphoma in octogenarians aged 85 and older can benefit from treatment with curative intent: a report on 129 patients prospectively registered in …
A Tucci, F Merli, A Fabbri, L Marcheselli… - …, 2022 - pmc.ncbi.nlm.nih.gov
Octogenarian patients with diffuse large B-cell lymphoma are managed mainly with
palliation, but recent improvement in their overall condition makes potentially curative …
palliation, but recent improvement in their overall condition makes potentially curative …
A simplified frailty score predicts survival and can aid treatment-intensity decisions in older patients with DLBCL
KT Isaksen, MA Mastroianni, M Rinde… - Blood …, 2021 - ashpublications.org
Patients with diffuse large B-cell lymphoma (DLBCL) have a median age of 70 years. Yet,
empirical knowledge about the treatment of older patients is limited because they are …
empirical knowledge about the treatment of older patients is limited because they are …
Impact of intended and relative dose intensity of R‐CHOP in a large, consecutive cohort of elderly diffuse large B‐cell lymphoma patients treated with curative intent …
TA Eyre, N Martinez‐Calle, C Hildyard… - Journal of internal …, 2019 - Wiley Online Library
Background The increasing incidence of diffuse large B‐cell lymphoma (DLBCL) in ageing
populations places a significant burden on healthcare systems. Co‐morbidity, frailty, and …
populations places a significant burden on healthcare systems. Co‐morbidity, frailty, and …
The minimal residual disease in non-Hodgkin's lymphomas: from the laboratory to the clinical practice
Minimal residual disease (MRD) in non-Hodgkin's lymphomas (NHLs) still represents matter
of interest and debate: indeed, the new available treatments offer higher rates of complete …
of interest and debate: indeed, the new available treatments offer higher rates of complete …